Investigational drug · Phase 3
ZL-1310
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumors, Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "ZL-1310"
First trial start
2025
May 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ZL-1310", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumors
- Small Cell Lung Cancer
- Large Cell Neuroendocrine Lung Carcinoma
- Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
- Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
- Small-cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ZL-1310" as an intervention, largest first.
- A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)Pivotal-lookingRecruiting
Zai Lab (Shanghai) Co., Ltd.Industry
NCT07218146 · 480 participants (planned) · Start Nov 30, 2025 · Primary completion Jun 30, 2028
Drug: ZL-1310; Investigator's Choice of Therapy · For: Small-cell Lung Cancer
Sites: La Jolla, California; Sacramento, California; Aurora, Colorado · 165 sites in all
Zai Lab (Shanghai) Co., Ltd.Industry
NCT06179069 · 339 participants (planned) · Start Jan 23, 2024 · Primary completion May 30, 2027
Drug: ZL-1310; Atezolizumab and 1 more · For: SCLC
Sites: Duarte, California; New Haven, Connecticut; Sarasota, Florida · 41 sites in all
Zai Lab (Shanghai) Co., Ltd.Industry
NCT06885281 · 166 participants (planned) · Start May 12, 2025 · Primary completion Aug 2027
Drug: ZL-1310 · For: Solid Tumors
Sites: San Francisco, California; Peoria, Illinois; Detroit, Michigan · 23 sites in all
AmgenAmgen (AMGN)
NCT07531095 · 160 participants (planned) · Start Apr 21, 2026 · Primary completion May 21, 2028
Drug: ZL-1310; Tarlatamab and 1 more · For: Small Cell Lung Cancer
Sites: Goodyear, Arizona; Tampa, Florida; Zion, Illinois · 27 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT07707895 · 60 participants (planned) · Start Nov 3, 2026 · Primary completion Apr 26, 2030
Drug: Obrixtamig; ZL-1310 and 1 more · For: Small Cell Lung Cancer; Large Cell Neuroendocrine Lung Carcinoma; Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology and 1 more
Sites: Washington D.C., District of Columbia; Tampa, Florida; Lexington, Kentucky · 28 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Addressing Unmet Needs in the Management of Small Cell Lung Cancer: Treatment of Brain Metastases, Quality of Life, and the Role of Real-World Evidence.
Dai Y, Fei J · Curr Treat Options Oncol 2026
- ADC for SCLC Clears Phase I.
· Cancer Discov 2026
- Redefining the Fight Against SCLC: Standards, Innovations, and New Horizons.
Kemper M, Reitnauer LE, Lenz G, et al. · Cancers (Basel) 2025
Also in development for Solid Tumors
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.